Q-Switched Nd:YAG in Macular Amyloidosis

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00353392

Enrollment

Registered

2006-07-18

Start date

2006-03-31

Completion date

2006-08-31

Last updated

2013-12-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Macular Amyloidosis

Brief summary

The purpose of this study is to determine whether Q-Switched Nd:YAG Laser therapy are effective in reduction of Cutaneous macular amyloidosis.

Detailed description

We treat the macular amyloidosis cases by Q-Switched Nd:YAG Laser and compare the before and after treatment situation by the photos and colorimetric assessment.

Interventions

DEVICELaser Therapy

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE

Eligibility

Sex/Gender

ALL

Age

18 Years to 70 Years

Healthy volunteers

Yes

Inclusion criteria

* Macular amyloidosis confirmed cases

Exclusion criteria

* Pregnancy and breast feeding * Over 18 years old

Design outcomes

Primary

Measure	Time frame
Visual and colorimetric assessment	—

Countries

Iran

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026